Pharmacokinetics of R-BI 1015550 After Single Oral Doses of BI 1015550 in Japanese Healthy Male Subjects (Open-label, Non-randomised, and Parallel Group Design)
Latest Information Update: 21 Mar 2024
Price :
$35 *
At a glance
- Drugs Nerandomilast (Primary)
- Indications Idiopathic pulmonary fibrosis; Interstitial lung diseases
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 27 Feb 2024 Status changed from active, no longer recruiting to completed.
- 09 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 22 Dec 2023 Planned End Date changed from 1 Mar 2024 to 14 Feb 2024.